Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Avanos Medical (AVNS) Shares Outstanding (2016 - 2026)

Avanos Medical's Shares Outstanding history spans 11 years, with the latest figure at $46.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1.07% to $46.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.5 million, a 1.07% increase, with the full-year FY2025 number at $46.5 million, up 1.07% from a year prior.
  • Shares Outstanding hit $46.5 million in Q4 2025 for Avanos Medical, roughly flat from $46.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding for AVNS hit a ceiling of $48.2 million in Q4 2021 and a floor of $45.9 million in Q2 2024.
  • Historically, Shares Outstanding has averaged $46.8 million across 5 years, with a median of $46.5 million in 2022.
  • Biggest five-year swings in Shares Outstanding: fell 3.48% in 2022 and later increased 1.07% in 2025.
  • Tracing AVNS's Shares Outstanding over 5 years: stood at $48.2 million in 2021, then dropped by 3.48% to $46.5 million in 2022, then decreased by 0.76% to $46.2 million in 2023, then dropped by 0.46% to $46.0 million in 2024, then grew by 1.07% to $46.5 million in 2025.
  • Business Quant data shows Shares Outstanding for AVNS at $46.5 million in Q4 2025, $46.4 million in Q3 2025, and $46.3 million in Q2 2025.